Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Change in Account Payables (2019 - 2023)

Alx Oncology Holdings' Change in Account Payables history spans 5 years, with the latest figure at -$4.5 million for Q4 2023.

  • For Q4 2023, Change in Account Payables fell 282.72% year-over-year to -$4.5 million; the TTM value through Dec 2023 reached $458000.0, down 89.84%, while the annual FY2025 figure was $421000.0, 110.46% up from the prior year.
  • Change in Account Payables for Q4 2023 was -$4.5 million at Alx Oncology Holdings, down from $8.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.9 million in Q3 2023 and bottomed at -$5.7 million in Q2 2023.
  • The 5-year median for Change in Account Payables is -$325000.0 (2020), against an average of $389444.4.
  • The largest annual shift saw Change in Account Payables crashed 581.88% in 2021 before it soared 843.64% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at $3.1 million in 2019, then crashed by 146.33% to -$1.4 million in 2020, then soared by 76.78% to -$330000.0 in 2021, then skyrocketed by 843.64% to $2.5 million in 2022, then crashed by 282.72% to -$4.5 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Change in Account Payables are -$4.5 million (Q4 2023), $8.9 million (Q3 2023), and -$5.7 million (Q2 2023).